Organ Transplant Denied by Insurance? UNOS Criteria and Coverage Appeals

Organ transplantation represents some of the most complex and consequential medical care in existence. When insurance coverage is denied for a transplant evaluation, listing, or the transplant procedure itself, the stakes could not be higher. Understanding the regulatory framework, insurer requirements, and appeal process is essential for patients and families navigating this crisis.

The UNOS Framework and Why It Matters for Insurance

The United Network for Organ Sharing (UNOS) administers the U.S. organ transplant system under federal contract with the Health Resources and Services Administration (HRSA). UNOS establishes the rules for:

• How patients are evaluated and listed for transplantation
• How organs are allocated among candidates
• Which transplant centers are authorized to perform each type of transplant

Insurance coverage for transplantation generally follows a parallel track: the medical team determines UNOS-based eligibility, and the insurer determines financial coverage. Problems arise when insurers impose criteria that conflict with or are more restrictive than UNOS guidelines, or when the insurer's contracted transplant center does not include the center where your care team practices.

Why Transplants Are Denied

Transplant center network limitations: Your insurer may only contract with certain transplant centers, and your hospital or transplant team may not be included.

Insurer-specific listing criteria: Commercial insurers sometimes require documentation that exceeds UNOS requirements — additional cardiac testing, psychiatric evaluation, or compliance monitoring.

Comorbidity exclusions: Obesity, active or recent malignancy, certain cardiovascular conditions, or substance use history may be cited as disqualifying factors, even when the transplant team has determined these are manageable.

Tier limitations in plan design: Some plan benefit designs place transplant coverage in a high-cost or limited-benefit tier that requires separate authorization and may have lifetime maximums.

Immunosuppressant coverage gaps: Even after a successful transplant, lifelong immunosuppressant medications may face coverage denials, gaps, or formulary restrictions that threaten graft survival.

CMS Conditions of Participation

Medicare-approved transplant centers must meet the CMS Conditions of Participation (CoPs) for transplant programs, which establish minimum volume requirements, outcome standards, and quality oversight processes. If an insurer directs you to a transplant center that does not meet CMS CoPs, that direction is medically inappropriate.

Conversely, if your transplant team practices at a CMS-certified, UNOS-member transplant center, that provides strong grounds to challenge any claim that the center is not qualified.

Transplant Evaluation and Listing Coverage

Insurance disputes often arise before the transplant itself — at the evaluation and listing stage. The transplant evaluation is a multi-disciplinary process that typically includes:

• Cardiology evaluation and stress testing
• Pulmonology and infectious disease clearance
• Nephrology or hepatology assessment
• Psychosocial evaluation and social work
• Financial and compliance counseling

Each component of the evaluation may be billed separately and may face individual Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements. Ensure that all evaluation components are pre-authorized if required, and appeal any denial of an evaluation component on medical necessity grounds.

Immunosuppressant Medication Coverage

Post-transplant immunosuppressant medications — including tacrolimus, mycophenolate mofetil, cyclosporine, and prednisone — are not optional maintenance medications. They are the biological foundation of graft survival. Failure to take these medications due to coverage gaps results in rejection, graft loss, and potentially death.

If your immunosuppressants are denied or subject to prohibitive cost-sharing post-transplant:

• Federal law (Medicare Improvement for Patients and Providers Act, MIPPA) provides limited Medicare Part B coverage for post-transplant immunosuppressants.
• Many state Medicaid programs provide indefinite immunosuppressant coverage post-transplant.
• Manufacturer patient assistance programs are available for most major immunosuppressants.
• Your transplant center social worker should be your first resource for navigating medication coverage.

How to Appeal a Transplant Denial

Step 1: Obtain the denial in writing with the specific clinical criteria cited.

Step 2: Have your transplant team write a comprehensive letter addressing each denial criterion with clinical data from your evaluation.

Step 3: Reference UNOS listing criteria and CMS CoPs to establish the standard of care.

Step 4: If the denial involves the transplant center's network status, request a single-case agreement or network exception for your center.

Step 5: File an expedited internal appeal, then move to External Independent Review: Complete Guide" class="auto-link">external review. Transplant denials often qualify for expedited review given medical urgency.

Step 6: Contact your state insurance commissioner and, for Medicare patients, your ESRD Network or HRSA regional office.

Fight Back With ClaimBack

Transplant coverage is lifesaving — not elective. ClaimBack helps you build the documentation to challenge denials at every stage of the transplant process.

Start your appeal with ClaimBack

Related Reading

• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which to File
• How to Write an Insurance Appeal Letter